Research programme: small molecules - Eli Lilly and Company/Schrodinger
Latest Information Update: 20 Dec 2023
At a glance
- Originator Schrodinger
- Developer Eli Lilly and Company; Schrodinger
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Immunological disorders
Most Recent Events
- 20 Dec 2023 Early research in Cancer in USA (unspecified route) (Schrodinger pipeline, December 2023)
- 20 Dec 2023 Early research in Immunological disorders in USA (unspecified route) (Schrodinger pipeline, December 2023)
- 06 Oct 2022 Eli Lilly and Company and Schrodinger enters into a collaboration for development of small molecule compounds